Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 6/20 | 0.46 |
| ▸ | CYBB | P04839 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17433840 | 0.84 | MEN1 (0.46) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17433767 | 0.82 | BACE1 (0.51) | BACE1KMT2ANCF1CYBBTP53 | |
| SCHEMBL17433795 | 0.78 | KDM4E (0.52) | BACE1MEN1KMT2ANCF1CYBB | |
| SCHEMBL5304396 | 0.75 | KMT2A (0.50) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL827255 | 0.74 | NSD2 (0.51) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17433794 | 0.72 | KMT2A (0.54) | BACE1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL13403458 | 0.71 | GABRP (0.65) | MEN1KMT2ASMN1; SMN2KDM4EGLA | |
| SCHEMBL10760283 | 0.71 | TSHR (0.72) | MEN1KMT2ASMN1; SMN2KDM4ECYP3A4 | |
| SCHEMBL10407111 | 0.71 | NR4A1 (0.59) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3085054 | 0.70 | CYP2D6 (0.45) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464076-B2 | Benzothiophene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-10-11 | — | — | US | disclosed |
| US-9464076-B2 | Benzothiophene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-10-11 | — | — | US | disclosed |
| US-9464076-B2 | Benzothiophene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-10-11 | — | — | US | disclosed |
| US-20160024060-A1 | BENZOTHIOPHENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20160024060-A1 | BENZOTHIOPHENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20160024060-A1 | BENZOTHIOPHENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
| EP-2975037-A1 | BENZOTHIOPHENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-20 | — | — | EP | disclosed |
| EP-2975037-A1 | BENZOTHIOPHENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024060-A1 | BENZOTHIOPHENE DERIVATIVE | PDE10A, PDE5A, PDE3B | BACE1 1405/4885MEN1 2442/4885KMT2A 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.